SCE Educational Library

Open category 1

• 1.1Defining a stem cellin review

  1. Self-renewal
  2. Differentiation
  3. Clonogenicity
  4. Potency
  5. Asymmetric and symmetric division
  6. Stem cells versus progenitor cells
  7. Stem cells versus mature cells
• 1.2Levels of developmental potentialin review

  1. Totipotency
  2. Pluripotency
  3. Multipotency
  4. Oligopotency
  5. Unipotency
  6. Functional tests of potency
• 1.3Major stem-cell categoriesin review

  1. Embryonic stem cells
  2. Induced pluripotent stem cells
  3. Adult or tissue-specific stem cells
  4. Hematopoietic stem cells
  5. Neural stem and progenitor cells
  6. Epithelial stem cells
  7. Muscle satellite cells
  8. Mesenchymal stromal cells
• 1.4Stem-cell nichesin review

  1. Extracellular matrix
  2. Supporting stromal cells
  3. Vascular signaling
  4. Oxygen tension
  5. Mechanical forces
  6. Inflammatory signaling
  7. Aging of the niche
• 1.5Cellular differentiationin review

  1. Lineage commitment
  2. Transcription factors
  3. Epigenetic regulation
  4. Cell signaling pathways
  5. Direct differentiation
  6. Transdifferentiation
  7. Reprogramming
• 1.6Stem-cell agingin review

  1. Replicative senescence
  2. Telomere biology
  3. DNA damage
  4. Mitochondrial dysfunction
  5. Epigenetic drift
  6. Donor-age effects
  7. Culture-related aging
• 1.7Sources of human cellsin review

  1. Bone marrow
  2. Peripheral blood
  3. Adipose tissue
  4. Dental tissues
  5. Placenta
  6. Umbilical-cord blood
  7. Umbilical-cord tissue
  8. Amniotic tissues
  9. Induced pluripotent cells
• 1.8Essential terminologyin review

  1. Autologous
  2. Allogeneic
  3. Syngeneic
  4. Xenogeneic
  5. Homologous use
  6. Minimal manipulation
  7. Cell therapy
  8. Gene-modified cell therapy
  9. Regenerative medicine

Open category 2

• 2.1What qualifies as an established therapy?in review

  1. Regulatory authorization
  2. Reproducible clinical benefit
  3. Accepted indications
  4. Standardized manufacturing
  5. Professional guidelines
  6. Postmarketing surveillance
• 2.2Hematopoietic stem-cell transplantationin review

  1. Bone-marrow transplantation
  2. Peripheral-blood stem-cell transplantation
  3. Cord-blood transplantation
  4. Autologous transplantation
  5. Allogeneic transplantation
• 2.3Established hematopoietic indicationsin review

  1. Leukemias
  2. Lymphomas
  3. Multiple myeloma
  4. Myelodysplastic syndromes
  5. Aplastic anemia
  6. Hemoglobinopathies
  7. Congenital immunodeficiencies
  8. Selected inherited metabolic diseases
• 2.4Transplantation fundamentalsin review

  1. Donor selection
  2. HLA matching
  3. Conditioning regimens
  4. Stem-cell mobilization
  5. Collection and processing
  6. Engraftment
  7. Immune reconstitution
  8. Long-term follow-up
• 2.5Transplantation complicationsin review

  1. Graft-versus-host disease
  2. Graft failure
  3. Infection
  4. Organ toxicity
  5. Infertility
  6. Secondary malignancies
  7. Relapse
  8. Late immune complications
• 2.6Experimental cell therapiesin review

  1. MSC-based therapies
  2. Pluripotent-cell-derived products
  3. Neural progenitor therapies
  4. Cardiac cell therapies
  5. Retinal cell therapies
  6. Pancreatic islet-cell replacement
  7. Tissue-engineered products
• 2.7Understanding regulatory statusin review

  1. Approved product
  2. Investigational product
  3. IND authorization
  4. Clinical-trial registration
  5. Expanded access
  6. Off-label use
  7. Unapproved commercial treatment
• 2.8Why a clinical trial is not proofin review

  1. Early-phase safety studies
  2. Lack of control groups
  3. Small sample size
  4. Surrogate endpoints
  5. Publication bias
  6. Incomplete follow-up
  7. Trial registration versus regulatory approval

Open category 3

• 3.1History of MSC researchin review

  1. Discovery in bone marrow
  2. Colony-forming fibroblasts
  3. Evolution of MSC terminology
  4. Expansion into multiple tissue sources
• 3.2“Stromal” versus “stem”in review

  1. Scientific basis for each term
  2. Limitations of the “stem-cell” label
  3. Functional proof of stemness
  4. Marketing misuse of terminology
• 3.3Minimal characterization criteriain review

  1. Plastic adherence
  2. CD73 expression
  3. CD90 expression
  4. CD105 expression
  5. Exclusion markers
  6. In-vitro trilineage differentiation
  7. Limitations of minimal criteria
• 3.4MSC heterogeneityin review

  1. Donor variability
  2. Tissue-source variability
  3. Colony-to-colony differences
  4. Passage-related changes
  5. Culture-medium effects
  6. Manufacturing-site effects
• 3.5Proposed biological functionsin review

  1. Stromal support
  2. Immunomodulation
  3. Paracrine signaling
  4. Angiogenic signaling
  5. Antifibrotic activity
  6. Cytoprotection
  7. Extracellular-matrix remodeling
• 3.6MSC interactions with immunityin review

  1. T lymphocytes
  2. B lymphocytes
  3. Natural-killer cells
  4. Dendritic cells
  5. Macrophages
  6. Neutrophils
  7. Complement
• 3.7MSC fate after administrationin review

  1. Pulmonary first-pass effect
  2. Biodistribution
  3. Survival
  4. Apoptosis
  5. Phagocytosis
  6. Engraftment
  7. Clearance
  8. Implications for mechanism of action
• 3.8Autologous versus allogeneic MSCsin review

  1. Availability
  2. Donor health
  3. Manufacturing time
  4. Immune compatibility
  5. Alloimmunization
  6. Batch consistency
  7. Scalability
  8. Cost
• 3.9MSC potencyin review

  1. Potency versus viability
  2. Immunomodulatory assays
  3. Angiogenic assays
  4. Secretome assays
  5. Matrix-remodeling assays
  6. Disease-specific potency assays
  7. Challenges in defining release criteria

Open category 4

• 4.1Umbilical-cord anatomyin review

  1. Amnion
  2. Wharton’s jelly
  3. Umbilical arteries
  4. Umbilical vein
  5. Perivascular regions
  6. Subamniotic regions
• 4.2Cord blood versus cord tissuein review

  1. Hematopoietic progenitor cells
  2. Mesenchymal stromal cells
  3. Cell composition
  4. Established uses
  5. Investigational uses
  6. Common public confusion
• 4.3Sources of cord-derived MSCsin review

  1. Whole-cord explants
  2. Wharton’s jelly
  3. Perivascular tissue
  4. Cord lining
  5. Vascular tissue
  6. Source-dependent variability
• 4.4Donation and procurementin review

  1. Maternal consent
  2. Donor medical history
  3. Infectious-disease screening
  4. Birth and delivery variables
  5. Collection technique
  6. Transport conditions
  7. Processing timelines
• 4.5Isolation methodsin review

  1. Explant migration
  2. Enzymatic digestion
  3. Mechanical dissociation
  4. Cell selection
  5. Initial plating
  6. Colony expansion
• 4.6Proposed advantagesin review

  1. Noninvasive collection
  2. Rapid proliferation
  3. Early developmental age
  4. Allogeneic manufacturing potential
  5. Secretory activity
  6. Immunomodulatory properties
• 4.7Limitations and uncertaintiesin review

  1. Donor heterogeneity
  2. Tissue-region variability
  3. Culture adaptation
  4. Senescence
  5. Immune recognition
  6. Thrombogenic potential
  7. Lack of product equivalence
• 4.8Cord-blood bankingin review

  1. Public banking
  2. Private banking
  3. Collection standards
  4. HLA typing
  5. Cell-dose requirements
  6. Storage
  7. Release testing
  8. Realistic probability of use
• 4.9Marketing terminology requiring scrutinyin review

  1. “Umbilical-cord stem cells”
  2. “Wharton’s-jelly stem cells”
  3. “Birth-tissue products”
  4. “Young cells”
  5. “Immune privileged”
  6. “FDA registered”
  7. “Clinical grade”

Open category 5

• 5.1Tissue procurementin review

  1. Donor eligibility
  2. Consent
  3. Aseptic collection
  4. Collection materials
  5. Transport temperature
  6. Time to processing
• 5.2Initial processingin review

  1. Tissue washing
  2. Dissection
  3. Digestion
  4. Filtration
  5. Centrifugation
  6. Initial cell recovery
  7. Cell counting
• 5.3Culture systemsin review

  1. Two-dimensional culture
  2. Three-dimensional culture
  3. Cell factories
  4. Bioreactors
  5. Microcarriers
  6. Closed-system processing
• 5.4Culture mediain review

  1. Fetal bovine serum
  2. Human platelet lysate
  3. Serum-free media
  4. Xeno-free media
  5. Chemically defined media
  6. Antibiotic use
  7. Growth-factor supplementation
• 5.5Cell expansionin review

  1. Passage number
  2. Population doublings
  3. Seeding density
  4. Confluence
  5. Harvest methods
  6. Culture duration
  7. Scale-up
• 5.6Cryopreservationin review

  1. Cryoprotectants
  2. Controlled-rate freezing
  3. Storage temperature
  4. Thawing
  5. Washing
  6. Post-thaw recovery
  7. Post-thaw functional changes
• 5.7Identity testingin review

  1. Surface markers
  2. Morphology
  3. Differentiation
  4. Gene-expression profiles
  5. Functional assays
  6. Tissue-source confirmation
• 5.8Safety testingin review

  1. Sterility
  2. Mycoplasma
  3. Endotoxin
  4. Adventitious viruses
  5. Donor-transmitted infections
  6. Tumorigenicity
  7. Genetic stability
• 5.9Product-quality attributesin review

  1. Identity
  2. Purity
  3. Viability
  4. Potency
  5. Dose
  6. Consistency
  7. Stability
• 5.10Comparabilityin review

  1. Manufacturing changes
  2. New culture media
  3. New equipment
  4. Facility transfer
  5. Scale-up
  6. Revised cryopreservation
  7. New analytical assays

Open category 6

• 6.1Extracellular-particle terminologyin review

  1. Extracellular vesicles
  2. Small extracellular vesicles
  3. Large extracellular vesicles
  4. Ectosomes
  5. Microvesicles
  6. Apoptotic bodies
  7. Nonvesicular extracellular particles
• 6.2What is an exosome?in review

  1. Endosomal origin
  2. Multivesicular bodies
  3. Vesicle release
  4. Why size alone cannot establish exosome identity
  5. Appropriate use of “EV” terminology
• 6.3EV compositionin review

  1. Membrane lipids
  2. Surface proteins
  3. Cytosolic proteins
  4. mRNA
  5. MicroRNA
  6. Other noncoding RNA
  7. DNA and mitochondrial components
• 6.4EV biogenesisin review

  1. Endosomal pathways
  2. Plasma-membrane budding
  3. Cargo sorting
  4. Rab proteins
  5. ESCRT-dependent pathways
  6. ESCRT-independent pathways
• 6.5EV uptakein review

  1. Receptor binding
  2. Endocytosis
  3. Membrane fusion
  4. Phagocytosis
  5. Cargo release
  6. Target-cell specificity
• 6.6MSC-derived EVsin review

  1. Relationship to MSC biology
  2. Immunomodulatory cargo
  3. Angiogenic signaling
  4. Antifibrotic signaling
  5. Tissue-repair hypotheses
  6. Differences from living-cell products
• 6.7EV separation methodsapproved

  Read topic 6.7

  1. Differential centrifugation
  2. Ultracentrifugation
  3. Density gradients
  4. Size-exclusion chromatography
  5. Ultrafiltration
  6. Tangential-flow filtration
  7. Precipitation
  8. Immunoaffinity capture
• 6.8EV characterizationapproved

  Read topic 6.8

  1. Particle concentration
  2. Particle size
  3. Electron microscopy
  4. Flow cytometry
  5. Western blotting
  6. Proteomics
  7. Lipidomics
  8. RNA analysis
  9. Single-vesicle analysis
• 6.9Purity and contaminantsapproved

  Read topic 6.9

  1. Protein aggregates
  2. Lipoproteins
  3. Cell debris
  4. Media-derived particles
  5. Serum-derived EVs
  6. Viruses
  7. Residual processing materials
• 6.10EV potency and doseapproved

  Read topic 6.10

  1. Particle number
  2. Protein quantity
  3. Cell-equivalent dose
  4. Cargo-based dosing
  5. Functional assays
  6. Dose-response testing
  7. Lack of universal dosing standards
• 6.11EV storage and stabilityapproved

  Read topic 6.11

  1. Temperature
  2. Buffer composition
  3. Freeze–thaw cycles
  4. Container effects
  5. Aggregation
  6. Sterility
  7. Shelf life
• 6.12Exosome marketing claimsapproved

  Read topic 6.12

  1. Particle counts without purity data
  2. Undefined source cells
  3. Unvalidated potency
  4. “Stem-cell-free” safety claims
  5. Cosmetic versus therapeutic claims
  6. Research-use-only products used clinically

Open category 7

• 7.1Cell replacement versus signalingapproved

  Read topic 7.1

  1. Direct engraftment
  2. Differentiation
  3. Paracrine effects
  4. Immune-mediated effects
  5. Matrix remodeling
• 7.2Immunomodulationapproved

  Read topic 7.2

  1. Proinflammatory and anti-inflammatory signaling
  2. T-cell regulation
  3. Macrophage phenotype
  4. Dendritic-cell modulation
  5. Natural-killer-cell effects
  6. Complement interactions
• 7.3Tissue protectionapproved

  Read topic 7.3

  1. Antiapoptotic signaling
  2. Oxidative-stress reduction
  3. Mitochondrial effects
  4. Autophagy
  5. Cytoprotection
  6. Metabolic support
• 7.4Angiogenesisapproved

  Read topic 7.4

  1. Endothelial-cell activation
  2. Vascular growth factors
  3. Pericyte interactions
  4. Vessel maturation
  5. Pathological angiogenesis risks
• 7.5Fibrosis and remodelingapproved

  Read topic 7.5

  1. Fibroblast activity
  2. Myofibroblast differentiation
  3. Collagen deposition
  4. Matrix metalloproteinases
  5. Scar remodeling
  6. Organ-specific fibrosis
• 7.6Mitochondrial transferapproved

  Read topic 7.6

  1. Tunneling nanotubes
  2. EV-associated transfer
  3. Functional consequences
  4. Evidence limitations
• 7.7Apoptotic-cell mechanismsapproved

  Read topic 7.7

  1. MSC apoptosis after infusion
  2. Efferocytosis
  3. Macrophage reprogramming
  4. Implications for short cell persistence
• 7.8Mechanism-of-action uncertaintyapproved

  Read topic 7.8

  1. Product-specific mechanisms
  2. Disease-specific mechanisms
  3. Dose dependence
  4. Timing
  5. Patient heterogeneity
  6. Why biological plausibility is not clinical proof

Open category 8

• 8.1Hematologyapproved

  Read topic 8.1

  1. Hematopoietic transplantation
  2. Marrow failure
  3. Hemoglobinopathies
  4. Graft-versus-host disease
  5. Immune reconstitution
• 8.2Musculoskeletal medicineapproved

  Read topic 8.2

  1. Knee osteoarthritis
  2. Hip osteoarthritis
  3. Cartilage defects
  4. Tendon injury
  5. Ligament injury
  6. Rotator-cuff disease
  7. Meniscal injury
  8. Bone defects
  9. Nonunion
  10. Intervertebral-disc disease
• 8.3Neurologyapproved

  Read topic 8.3

  1. Ischemic stroke
  2. Hemorrhagic stroke
  3. Traumatic brain injury
  4. Spinal-cord injury
  5. Multiple sclerosis
  6. Parkinson’s disease
  7. Alzheimer’s disease
  8. ALS
  9. Peripheral neuropathy
• 8.4Cardiovascular diseaseapproved

  Read topic 8.4

  1. Myocardial infarction
  2. Ischemic cardiomyopathy
  3. Heart failure
  4. Peripheral arterial disease
  5. Critical limb ischemia
  6. Endothelial dysfunction
• 8.5Pulmonary diseaseapproved

  Read topic 8.5

  1. Acute respiratory distress syndrome
  2. Chronic obstructive pulmonary disease
  3. Pulmonary fibrosis
  4. Bronchopulmonary dysplasia
  5. Pulmonary hypertension
  6. Postinfectious lung injury
• 8.6Autoimmune and inflammatory diseaseapproved

  Read topic 8.6

  1. Rheumatoid arthritis
  2. Systemic lupus erythematosus
  3. Systemic sclerosis
  4. Sjögren syndrome
  5. Inflammatory bowel disease
  6. Type 1 diabetes
  7. Immune dysregulation
• 8.7Liver and gastrointestinal diseaseapproved

  Read topic 8.7

  1. Cirrhosis
  2. Acute liver failure
  3. Metabolic liver disease
  4. Crohn’s fistulas
  5. Ulcerative colitis
  6. Intestinal injury
• 8.8Kidney diseaseapproved

  Read topic 8.8

  1. Acute kidney injury
  2. Chronic kidney disease
  3. Diabetic kidney disease
  4. Transplant-related injury
  5. Renal fibrosis
• 8.9Endocrine and metabolic diseaseapproved

  Read topic 8.9

  1. Type 1 diabetes
  2. Type 2 diabetes complications
  3. Islet-cell replacement
  4. Obesity-associated inflammation
  5. Metabolic syndrome
• 8.10Ophthalmologyapproved

  Read topic 8.10

  1. Retinal degeneration
  2. Macular degeneration
  3. Optic-nerve injury
  4. Corneal disease
  5. Diabetic retinopathy
  6. Documented risks of unapproved ocular injections
• 8.11Dermatology and wound careapproved

  Read topic 8.11

  1. Diabetic ulcers
  2. Pressure injuries
  3. Burns
  4. Radiation injury
  5. Scar remodeling
  6. Alopecia
  7. Cosmetic skin claims
• 8.12Reproductive medicineapproved

  Read topic 8.12

  1. Endometrial injury
  2. Ovarian insufficiency
  3. Erectile dysfunction
  4. Infertility claims
  5. Evidence and ethical limitations
• 8.13Pediatricsapproved

  Read topic 8.13

  1. Cerebral palsy
  2. Hypoxic-ischemic injury
  3. Autism claims
  4. Genetic diseases
  5. Pediatric consent and assent
  6. Long-term developmental surveillance
• 8.14Oncologyapproved

  Read topic 8.14

  1. Treatment-related tissue injury
  2. Bone-marrow support
  3. Tumor microenvironment
  4. Potential tumor-promoting effects
  5. EVs as biomarkers
  6. Engineered EV drug delivery
• 8.15Longevity and “anti-aging”approved

  Read topic 8.15

  1. Biological-aging claims
  2. Frailty
  3. Sarcopenia
  4. Cognitive aging
  5. Sexual-health claims
  6. Absence of validated rejuvenation endpoints

Open category 9

• 9.1The translational pathwayapproved

  Read topic 9.1

  1. Discovery
  2. Proof of concept
  3. Animal studies
  4. Toxicology
  5. Phase 1
  6. Phase 2
  7. Phase 3
  8. Regulatory review
  9. Postmarketing surveillance
• 9.2Preclinical evidenceapproved

  Read topic 9.2

  1. In-vitro models
  2. Organoids
  3. Small-animal models
  4. Large-animal models
  5. Disease-model validity
  6. Reproducibility
  7. Translation failures
• 9.3Trial designapproved

  Read topic 9.3

  1. Randomization
  2. Allocation concealment
  3. Blinding
  4. Placebo controls
  5. Active controls
  6. Sham procedures
  7. Multicenter trials
• 9.4Study populationsapproved

  Read topic 9.4

  1. Eligibility criteria
  2. Disease severity
  3. Prior treatment
  4. Comorbidities
  5. Age
  6. Sex
  7. Race and ethnicity
  8. Generalizability
• 9.5Outcomesapproved

  Read topic 9.5

  1. Safety endpoints
  2. Biomarkers
  3. Imaging
  4. Functional outcomes
  5. Patient-reported outcomes
  6. Quality of life
  7. Survival
  8. Clinically meaningful differences
• 9.6Statistical interpretationapproved

  Read topic 9.6

  1. Sample size
  2. Statistical power
  3. Confidence intervals
  4. Multiple comparisons
  5. Missing data
  6. Subgroup analysis
  7. Intention-to-treat analysis
• 9.7Bias and transparencyapproved

  Read topic 9.7

  1. Selection bias
  2. Performance bias
  3. Detection bias
  4. Attrition bias
  5. Selective reporting
  6. Sponsorship bias
  7. Publication bias
• 9.8Evidence hierarchiesapproved

  Read topic 9.8

  1. Case reports
  2. Case series
  3. Observational studies
  4. Controlled trials
  5. Randomized trials
  6. Systematic reviews
  7. Meta-analyses
  8. Guidelines
• 9.9Evidence gradingapproved

  Read topic 9.9

  1. Certainty of evidence
  2. Magnitude of effect
  3. Consistency
  4. Directness
  5. Precision
  6. Risk-benefit balance
• 9.10Reading trial registriesapproved

  Read topic 9.10

  1. Registration number
  2. Sponsor
  3. Study phase
  4. Recruitment status
  5. Primary endpoint
  6. Results posting
  7. IND claims
  8. Why registration does not equal endorsement

Open category 10

• 10.1Defining dosein preparation

  1. Total cells
  2. Cells per kilogram
  3. Viable cells
  4. Particle number
  5. Protein content
  6. Cell-equivalent EV dose
  7. Functional potency
• 10.2Route of administrationin preparation

  1. Intravenous
  2. Intra-arterial
  3. Intramuscular
  4. Intra-articular
  5. Intrathecal
  6. Intracerebral
  7. Intramyocardial
  8. Intranasal
  9. Inhaled
  10. Topical
  11. Scaffold-based delivery
• 10.3Local versus systemic deliveryin preparation

  1. Target exposure
  2. Biodistribution
  3. First-pass trapping
  4. Procedure risks
  5. Repeatability
  6. Product loss
• 10.4Timingin preparation

  1. Acute injury
  2. Subacute disease
  3. Chronic disease
  4. Inflammatory phase
  5. Repair phase
  6. Relationship to standard treatment
• 10.5Repeat dosingin preparation

  1. Biological rationale
  2. Dose intervals
  3. Immune sensitization
  4. Cumulative risk
  5. Durability
  6. Cost
• 10.6Product preparationin preparation

  1. Fresh versus frozen
  2. Thawing
  3. Washing
  4. Resuspension
  5. Infusion media
  6. Time from preparation to administration
• 10.7Administration monitoringin preparation

  1. Baseline assessment
  2. Vital signs
  3. Infusion reactions
  4. Emergency preparedness
  5. Laboratory monitoring
  6. Postprocedure observation
• 10.8Dose optimizationin preparation

  1. Dose escalation
  2. Maximum tolerated dose
  3. Minimum effective dose
  4. Biological effective dose
  5. Exposure-response relationships
  6. Personalized dosing claims

Open category 11

• 11.1Immediate reactionsin preparation

  1. Fever
  2. Chills
  3. Hypersensitivity
  4. Anaphylaxis
  5. Hypotension
  6. Hypertension
  7. Respiratory symptoms
• 11.2Infection risksin preparation

  1. Donor-derived infection
  2. Processing contamination
  3. Bacteremia
  4. Sepsis
  5. Mycoplasma
  6. Viral transmission
  7. Mold contamination
• 11.3Immune risksin preparation

  1. Alloimmunization
  2. Antibody formation
  3. Complement activation
  4. Cytokine responses
  5. Autoimmune activation
  6. Immunosuppression
• 11.4Thrombotic and embolic risksin preparation

  1. Tissue factor
  2. Coagulation activation
  3. Microvascular obstruction
  4. Venous thrombosis
  5. Pulmonary embolic phenomena
  6. Stroke risk
• 11.5Abnormal tissue growthin preparation

  1. Ectopic tissue
  2. Fibrosis
  3. Calcification
  4. Uncontrolled proliferation
  5. Tumor formation
  6. Tumor-supporting signaling
• 11.6Procedure-specific risksin preparation

  1. Intra-articular injection
  2. Intrathecal injection
  3. Intracranial delivery
  4. Intraocular injection
  5. Intra-arterial delivery
  6. Sedation and anesthesia
• 11.7Organ-specific complicationsin preparation

  1. Neurological injury
  2. Blindness
  3. Pulmonary injury
  4. Cardiac complications
  5. Renal injury
  6. Hepatic injury
• 11.8Contraindications and precautionsin preparation

  1. Active infection
  2. Unstable malignancy
  3. Coagulopathy
  4. Severe cardiopulmonary disease
  5. Pregnancy
  6. Immunosuppression
  7. Product-specific exclusions
• 11.9Long-term surveillancein preparation

  1. Delayed adverse events
  2. Malignancy surveillance
  3. Autoimmunity
  4. Organ dysfunction
  5. Reproductive effects
  6. Registries
  7. Loss to follow-up
• 11.10Adverse-event reportingin preparation

  1. Clinic reporting
  2. Sponsor reporting
  3. IRB reporting
  4. FDA MedWatch
  5. Product traceability
  6. Patient documentation

Open category 12

• 12.1Good Manufacturing Practicein preparation

  1. Facility requirements
  2. Personnel training
  3. Controlled environments
  4. Documentation
  5. Deviation management
  6. Corrective and preventive action
• 12.2Cleanroom operationsin preparation

  1. Air classification
  2. Environmental monitoring
  3. Gowning
  4. Aseptic technique
  5. Cleaning
  6. Contamination control
• 12.3Starting materialsin preparation

  1. Donor tissue
  2. Culture media
  3. Supplements
  4. Enzymes
  5. Disposable systems
  6. Reagent qualification
• 12.4Cell banksin preparation

  1. Master cell bank
  2. Working cell bank
  3. Donor traceability
  4. Qualification
  5. Storage
  6. Inventory controls
• 12.5In-process controlsin preparation

  1. Cell density
  2. Morphology
  3. Growth kinetics
  4. Culture conditions
  5. Contamination monitoring
  6. Harvest timing
• 12.6Release testingin preparation

  1. Identity
  2. Purity
  3. Viability
  4. Potency
  5. Sterility
  6. Endotoxin
  7. Mycoplasma
  8. Dose verification
• 12.7EV manufacturingin preparation

  1. Source-cell qualification
  2. Conditioned-media collection
  3. EV separation
  4. Concentration
  5. Purification
  6. Contaminant removal
  7. Particle characterization
  8. Potency
• 12.8Stabilityin preparation

  1. Real-time stability
  2. Accelerated stability
  3. Shipping stability
  4. In-use stability
  5. Freeze–thaw stability
  6. Container closure
• 12.9Chain of identity and custodyin preparation

  1. Donor identification
  2. Sample labeling
  3. Batch records
  4. Product tracking
  5. Shipping documentation
  6. Administration records
• 12.10Manufacturing failuresin preparation

  1. Batch contamination
  2. Failed potency
  3. Low viability
  4. Product mix-ups
  5. Temperature excursions
  6. Deviations
  7. Recalls

Open category 13

• 13.1U.S. regulatory foundationsin preparation

  1. Drugs
  2. Biological products
  3. Human cells and tissues
  4. Public Health Service Act
  5. Food, Drug, and Cosmetic Act
  6. FDA/CBER oversight
• 13.2HCT/P frameworkin preparation

  1. Section 361 products
  2. Section 351 products
  3. Minimal manipulation
  4. Homologous use
  5. Systemic effect
  6. Dependence on metabolic activity
• 13.3Investigational New Drug applicationsin preparation

  1. Preclinical package
  2. Chemistry, manufacturing, and controls
  3. Clinical protocol
  4. Investigator qualifications
  5. Safety reporting
  6. FDA authorization to proceed
• 13.4Marketing authorizationin preparation

  1. Biologics License Application
  2. Evidence requirements
  3. Facility inspection
  4. Labeling
  5. Postmarketing commitments
• 13.5Expanded accessin preparation

  1. Individual-patient access
  2. Intermediate-size populations
  3. Treatment protocols
  4. Eligibility
  5. FDA and IRB roles
  6. Cost recovery
• 13.6Right-to-try lawsin preparation

  1. Eligibility
  2. Differences from expanded access
  3. Limitations
  4. Manufacturer discretion
  5. Financial risks
  6. Data collection
• 13.7Exosome regulationin preparation

  1. Drug and biological-product classification
  2. Investigational use
  3. Manufacturing controls
  4. Therapeutic claims
  5. Unapproved commercial distribution
  6. Research-use-only labeling
• 13.8Advertising and enforcementin preparation

  1. Disease-treatment claims
  2. Misbranding
  3. Warning letters
  4. Injunctions
  5. Product seizures
  6. Registration versus approval
• 13.9International regulationin preparation

  1. European Union
  2. United Kingdom
  3. Canada
  4. Australia
  5. Japan
  6. South Korea
  7. China
  8. Latin America
  9. Regulatory-tourism concerns
• 13.10Verifying regulatory statusin preparation

  1. FDA databases
  2. Approved labeling
  3. IND documentation
  4. ClinicalTrials.gov
  5. IRB information
  6. Foreign regulatory authorities
  7. Warning letters

Open category 14

• 14.1Ethical principlesin preparation

  1. Respect for persons
  2. Beneficence
  3. Nonmaleficence
  4. Justice
  5. Scientific validity
  6. Transparency
• 14.2Tissue donationin preparation

  1. Voluntary consent
  2. Maternal consent
  3. Privacy
  4. Genetic information
  5. Future research
  6. Commercial use
  7. Withdrawal limitations
• 14.3Research-participant protectionsin preparation

  1. IRB review
  2. Risk minimization
  3. Fair recruitment
  4. Vulnerable populations
  5. Data monitoring
  6. Compensation for injury
• 14.4Therapeutic misconceptionin preparation

  1. Research versus treatment
  2. Hope versus evidence
  3. Investigator language
  4. Participant expectations
  5. Commercial influence
• 14.5Patient-funded researchin preparation

  1. Scientific justification
  2. Financial conflicts
  3. Undue inducement
  4. Transparency
  5. Access inequality
  6. Data-quality concerns
• 14.6Informed-consent contentin preparation

  1. Experimental status
  2. Product source
  3. Manufacturing information
  4. Known risks
  5. Unknown risks
  6. Alternatives
  7. Costs
  8. Follow-up
  9. Injury management
• 14.7Conflicts of interestin preparation

  1. Physician ownership
  2. Manufacturer relationships
  3. Referral fees
  4. Sponsored research
  5. Intellectual property
  6. Disclosure
• 14.8Equity and accessin preparation

  1. Trial diversity
  2. Geographic access
  3. Affordability
  4. Insurance coverage
  5. Global disparities
  6. Post-trial access
• 14.9Special ethical topicsin preparation

  1. Embryonic stem cells
  2. iPSCs
  3. Genome editing
  4. Organoids
  5. Chimeras
  6. Stem-cell-based embryo models
  7. Reproductive applications

Open category 15

• 15.1Establishing the diagnosisin preparation

  1. Diagnostic certainty
  2. Disease stage
  3. Severity
  4. Prognosis
  5. Reversible causes
  6. Standard-care options
• 15.2Reviewing treatment historyin preparation

  1. Prior therapies
  2. Treatment adherence
  3. Contraindications
  4. Treatment failures
  5. Rehabilitation
  6. Surgical options
• 15.3Candidate assessmentin preparation

  1. Age
  2. Comorbidities
  3. Functional status
  4. Immune status
  5. Malignancy history
  6. Infection risk
  7. Coagulation risk
• 15.4Goals of treatmentin preparation

  1. Symptom control
  2. Functional improvement
  3. Disease modification
  4. Tissue regeneration
  5. Quality of life
  6. Cure claims
• 15.5Risk-benefit analysisin preparation

  1. Probability of benefit
  2. Severity of harm
  3. Uncertainty
  4. Alternative treatment
  5. Opportunity cost
  6. Financial toxicity
• 15.6Shared decision-makingin preparation

  1. Patient values
  2. Family participation
  3. Health literacy
  4. Decision aids
  5. Second opinions
  6. Documentation
• 15.7Clinical-trial suitabilityin preparation

  1. Eligibility
  2. Trial phase
  3. Randomization
  4. Placebo possibility
  5. Travel
  6. Follow-up
  7. Withdrawal
• 15.8Baseline documentationin preparation

  1. Symptoms
  2. Physical examination
  3. Laboratory studies
  4. Imaging
  5. Functional assessments
  6. Patient-reported outcomes
• 15.9Follow-up planningin preparation

  1. Early safety review
  2. Objective outcome measurement
  3. Rehabilitation
  4. Adverse-event monitoring
  5. Long-term surveillance
  6. Data sharing

Open category 16

• 16.1Common misleading phrasesin preparation

  1. “FDA registered”
  2. “FDA compliant”
  3. “Clinical grade”
  4. “No rejection”
  5. “Immune privileged”
  6. “Zero risk”
  7. “Guaranteed”
  8. “Repairs any tissue”
• 16.2Misuse of scientific evidencein preparation

  1. Animal studies presented as human proof
  2. One product used to support another
  3. Case reports presented as trials
  4. Abstract-only citations
  5. Selective outcome reporting
  6. Testimonials replacing data
• 16.3Misrepresentation of regulationin preparation

  1. Registration versus approval
  2. IND versus approval
  3. IRB review versus efficacy
  4. ClinicalTrials.gov listing versus endorsement
  5. Laboratory certification versus product authorization
• 16.4Product ambiguityin preparation

  1. Unspecified cell source
  2. Undefined cell count
  3. No viability data
  4. No potency data
  5. No certificate of analysis
  6. No manufacturer identification
  7. No batch number
• 16.5Exosome-specific red flagsin preparation

  1. Particle count without purity
  2. No EV characterization
  3. Unverified cargo claims
  4. “Billions of exosomes”
  5. No sterility or endotoxin testing
  6. Topical product promoted for systemic disease
• 16.6Clinic red flagsin preparation

  1. One product for unrelated diseases
  2. Sales pressure
  3. Same-day treatment
  4. Large upfront payment
  5. Financing incentives
  6. No emergency plan
  7. No long-term follow-up
• 16.7Marketing methodsin preparation

  1. Celebrity endorsements
  2. Influencer testimonials
  3. Before-and-after photographs
  4. Emotional patient stories
  5. Fear of conventional medicine
  6. Claims of regulatory conspiracy
• 16.8Financial warning signsin preparation

  1. Treatment bundles
  2. Pay-to-participate trials
  3. Nonrefundable deposits
  4. Cash-only policies
  5. Hidden follow-up costs
  6. Charges for complications
• 16.9How to investigate a claimin preparation

  1. Identify the exact product
  2. Locate the original study
  3. Verify the study population
  4. Verify regulatory status
  5. Review adverse events
  6. Obtain an independent specialist opinion

Open category 17

• 17.1Product identityin preparation

  1. What exactly is being administered?
  2. Is it a cell product, EV product, tissue product, or conditioned medium?
  3. What is the tissue source?
  4. Is it autologous or allogeneic?
  5. Who manufactured it?
  6. What is the batch number?
• 17.2Regulatory statusin preparation

  1. Is this product FDA-approved for my condition?
  2. If investigational, what is the IND number?
  3. Who is the sponsor?
  4. Which IRB approved the study?
  5. Where is the trial registered?
  6. May I review the FDA acknowledgment?
• 17.3Manufacturing and testingin preparation

  1. Was it manufactured under GMP?
  2. What sterility testing was performed?
  3. Was it tested for endotoxin and mycoplasma?
  4. What are the identity and purity specifications?
  5. What is the viability?
  6. What potency assay was used?
• 17.4Evidencein preparation

  1. What peer-reviewed trials studied this exact product?
  2. Were they randomized and controlled?
  3. How many patients were treated?
  4. What objective benefits occurred?
  5. How long were patients followed?
  6. Were negative results published?
• 17.5Risksin preparation

  1. What serious adverse events have occurred?
  2. What risks remain unknown?
  3. What are the procedure-specific risks?
  4. Could the therapy interfere with future treatment?
  5. Who manages complications?
  6. Where would emergency care occur?
• 17.6Treatment planin preparation

  1. What dose will I receive?
  2. How was that dose selected?
  3. What route will be used?
  4. Why is repeat dosing recommended?
  5. What other treatments are required?
  6. What follow-up is included?
• 17.7Costsin preparation

  1. What is the total cost?
  2. Are travel and follow-up included?
  3. Who pays for complications?
  4. Is any portion refundable?
  5. Is insurance expected to pay?
  6. Am I paying to participate in research?
• 17.8Alternativesin preparation

  1. What is the current standard of care?
  2. What happens without this intervention?
  3. Are less risky options available?
  4. Are legitimate trials available?
  5. Should I obtain a second opinion?
• 17.9Documentation to requestin preparation

  1. Informed-consent form
  2. Investigator brochure
  3. Protocol summary
  4. Certificate of analysis
  5. Manufacturer information
  6. Regulatory documentation
  7. Written follow-up plan

Open category 18

• 18.1MSC engineeringin preparation

  1. Genetic modification
  2. RNA engineering
  3. Surface modification
  4. Homing enhancement
  5. Suicide switches
  6. Safety controls
• 18.2MSC primingin preparation

  1. Hypoxia
  2. Inflammatory cytokines
  3. Mechanical stimulation
  4. Pharmacological priming
  5. Three-dimensional culture
  6. Disease-specific conditioning
• 18.3Advanced manufacturingin preparation

  1. Closed automated systems
  2. Continuous manufacturing
  3. Large-scale bioreactors
  4. Real-time monitoring
  5. Process analytical technology
  6. Artificial intelligence in quality control
• 18.4Engineered EVsin preparation

  1. Cargo loading
  2. Surface targeting
  3. RNA delivery
  4. Protein delivery
  5. Drug delivery
  6. Synthetic and hybrid vesicles
• 18.5EV biomarkersin preparation

  1. Cancer detection
  2. Neurological disease
  3. Cardiovascular disease
  4. Transplant monitoring
  5. Treatment response
  6. Liquid biopsy
• 18.6Tissue engineeringin preparation

  1. Biomaterial scaffolds
  2. Hydrogels
  3. Decellularized matrix
  4. Bioprinting
  5. Vascularized constructs
  6. Organoid transplantation
• 18.7Pluripotent-cell-derived therapiesin preparation

  1. Retinal cells
  2. Dopaminergic neurons
  3. Cardiomyocytes
  4. Pancreatic beta cells
  5. Immune cells
  6. Safety and tumorigenicity
• 18.8Organoids and disease modelsin preparation

  1. Developmental biology
  2. Drug screening
  3. Personalized medicine
  4. Toxicology
  5. Organoid transplantation
  6. Ethical issues
• 18.9Precision regenerative medicinein preparation

  1. Patient stratification
  2. Biomarker-guided therapy
  3. Pharmacogenomics
  4. Immune profiling
  5. Digital endpoints
  6. Individualized potency testing
• 18.10Better clinical trialsin preparation

  1. Adaptive designs
  2. Platform trials
  3. Master protocols
  4. Standardized core outcomes
  5. International registries
  6. Long-term surveillance networks
• 18.11Future regulatory challengesin preparation

  1. Engineered cells
  2. Combination products
  3. Decentralized manufacturing
  4. Personalized batches
  5. Artificial EVs
  6. Cross-border treatment
• 18.12Realistic future outlookin preparation

  1. Scientific opportunities
  2. Translational bottlenecks
  3. Manufacturing barriers
  4. Affordability
  5. Evidence requirements
  6. Preventing hype from outrunning data